598 related articles for article (PubMed ID: 24142549)
1. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition.
He Q; Shi J
Adv Mater; 2014 Jan; 26(3):391-411. PubMed ID: 24142549
[TBL] [Abstract][Full Text] [Related]
2. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
3. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
4. Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer.
Castillo RR; Colilla M; Vallet-RegĂ M
Expert Opin Drug Deliv; 2017 Feb; 14(2):229-243. PubMed ID: 27402029
[TBL] [Abstract][Full Text] [Related]
5. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
Beretta GL; Cavalieri F
Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
[TBL] [Abstract][Full Text] [Related]
6. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
7. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles.
Pan L; Liu J; He Q; Wang L; Shi J
Biomaterials; 2013 Apr; 34(11):2719-30. PubMed ID: 23337327
[TBL] [Abstract][Full Text] [Related]
8. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
Gote V; Nookala AR; Bolla PK; Pal D
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
[TBL] [Abstract][Full Text] [Related]
9. Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles.
Hanafi-Bojd MY; Ansari L; Malaekeh-Nikouei B
Ther Deliv; 2016 Sep; 7(9):649-55. PubMed ID: 27582236
[TBL] [Abstract][Full Text] [Related]
10. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
Kibria G; Hatakeyama H; Harashima H
Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
[TBL] [Abstract][Full Text] [Related]
11. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy.
Hussain Z; Arooj M; Malik A; Hussain F; Safdar H; Khan S; Sohail M; Pandey M; Choudhury H; Ei Thu H
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1015-1024. PubMed ID: 29873531
[TBL] [Abstract][Full Text] [Related]
12. Meta-Analysis of Efficacy of Chemotherapy Delivered by Mesoporous Silica Nanoparticles to Tumor-Bearing Mice.
McGoron A
Crit Rev Biomed Eng; 2020; 48(6):327-418. PubMed ID: 33641279
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis.
Li W; Guo Z; Zheng K; Ma K; Cui C; Wang L; Yuan Y; Tang Y
Int J Pharm; 2017 Dec; 534(1-2):71-80. PubMed ID: 28958879
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.
Mao C; Li F; Zhao Y; Debinski W; Ming X
Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297
[TBL] [Abstract][Full Text] [Related]
15. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
Zhang W; Liu M; Liu A; Zhai G
Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
[TBL] [Abstract][Full Text] [Related]
17. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional mesoporous silica nanoplatform based on silicon nanoparticles for targeted two-photon-excited fluorescence imaging-guided chemo/photodynamic synergetic therapy in vitro.
Li S; Zhang Y; He XW; Li WY; Zhang YK
Talanta; 2020 Mar; 209():120552. PubMed ID: 31892096
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance.
Tekchandani P; Kurmi BD; Paliwal SR
Mini Rev Med Chem; 2017; 17(18):1793-1810. PubMed ID: 26891930
[TBL] [Abstract][Full Text] [Related]
20. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance.
He Q; Gao Y; Zhang L; Zhang Z; Gao F; Ji X; Li Y; Shi J
Biomaterials; 2011 Oct; 32(30):7711-20. PubMed ID: 21816467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]